Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.54 |
| ▸ | WNT1 | P04628 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389260 | 0.89 | GPR119 (0.53) | EGFRERBB2WNT1GSK3BDYRK1A | |
| SCHEMBL4721873 | 0.84 | EGFR (0.47) | EGFRERBB2WNT1GSK3BDYRK1A | |
| SCHEMBL22598701 | 0.78 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL29751982 | 0.78 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL1070555 | 0.75 | GPR119 (0.47) | EGFRGPR119 | |
| SCHEMBL29751954 | 0.75 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL22598592 | 0.75 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL1830976 | 0.74 | GPR119 (0.45) | EGFRGPR119 | |
| SCHEMBL1573307 | 0.73 | EGFR (0.51) | EGFRERBB2WNT1GSK3BDYRK1A | |
| SCHEMBL1071293 | 0.72 | GPR119 (0.42) | EGFRERBB2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |